Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-08-14
1994-01-04
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514570, A61K 3144, A61K 3119
Patent
active
052760448
ABSTRACT:
Pharmaceutical compositions are disclosed which effectively treat the symptoms of hypersensitivity diseases without irritation. The pharmaceutical compositions are complexes of at least one leukotriene receptor antagonist and at least one antihistamine. The complexes can be formulated in low viscosity solutions for administering to an individual as an aerosol or drops or through intravenous, subcutaneous, or intramuscular injection. Alternatively, the complexes can be formulated in high viscosity creams for topical delivery to the skin or ocular environment.
REFERENCES:
patent: 4623535 (1986-11-01), Perchonock
patent: 4683325 (1987-07-01), Frenette et al.
Merck Index, Eleventh Edition, p. 1270, #7996 (1989).
Reprint from Journal of Medicinal Chemistry, vol. 30, No. 6, Jun. 1987, entitled "Communications to the Editor".
"Synthesis and Structure-Activity Relationship Studies of a Series of 5-Aryl-4, 6-dithianonanedioic Acids and Related Compounds: Novel Class of Leukotriene Antagonists", J. Med. Chem. 1986, 29, 1442-1452, C. D. Perchonock et al.
"Antagonists of Slow-Reacting Substance of Anaphylaxis, 1. Pyrido[2,1-b] quinazolinecarboxylic Acid Derivatives", J. Med. Chem., 1983, 26, 1638-1642, J. W. Tilley, et al.
"Leukotriene Receptor Antagonists 1. Synthesis and Structure-Activity Relationships of Alkoxyacetophenone Derivatives", J. Med. Chem. 1987, 30, 682-689, W. S. Marshall, et al.
"Antagonism of the in vivo and in vitro effects of leukotriene D.sub.4 by SC-39070 in guinea pigs", Agents and Actions, vol. 20, 22/33 (1987), G. W. Carnathan, et al.
Pp. 695, 697, 805 and 807 from "Drugs of the Future", vol. 15 Nos. 7 and 8, 1990.
"Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity", European Journal of Pharmacology, (1989) 323-333, D. F. Woodward, et al.
"5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in guinea-pig", European Journal of Pharmacology, 143, (1987) 1-7, D. Garceau et al.
"Pharmacology of Histamine Receptors"; C. R. Ganellin, et al Wright P. S. G., 1982 (pp. 60-62).
Pp. 736-739; "Drugs of the Future", vol. VII, No. 10 1982 (S. J. Hopkins).
Pp. 695 & 697 "Drugs of the Future", vol. 15, No. 7, 1990 & pp. 805 & 807, vol. 15, No. 8, 1990.
"Communications to the Editor", Journal of Medicinal Chemistry, 1987, vol. 30, No. 6, pp. 959-961.
Fishleder, et al., "An examination of the ability of dtubocurarine to evoke contraction and mediator release from superfused trachea adn parenchymal strips isolated from the guinea pig", J. Pharmacol. Exp. Ther., (8/87), 242(2), 558-565.
V. B. Weg, et al., "Histamine, leukotriene D4 and plactelet-activating factor in guinea pig passive cutaneous anaphylaxis", Eur. J. Pharmacol. 1991, 204(2), 157-163.
Schachter, et al., "Pharmacologic studies of cotton bract extract in isolated guinea pig trachea", Cotton Dust, 1988, 12th, 90-1.
Ambrus Gyorgy F.
Himmelstein Kenneth J.
Woodward David F.
Allergan Inc.
Criares T. J.
Waddell Frederick E.
LandOfFree
Leukotriene receptor antagonist and antihistamine complex pharma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leukotriene receptor antagonist and antihistamine complex pharma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leukotriene receptor antagonist and antihistamine complex pharma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307485